Curated dataset · n=61 verified deals · Not live market data · Scores are descriptive, not forecasts.
You are here

Deals — Network graph, deal flow, valuation matrix, and acquirer landscape.

Invitae Reproductive Health
→
Natera

Asset Acquisition · Cash (asset acquisition) · NTRA · announced Jan 22, 2024

View in network
  1. Announced

    Jan 22, 2024

  2. Closed

    Jan 22, 2024

Economics

Cash (asset acquisition)()

Pre-deal · pre-deal mark: 2024, year precision · Natera 8-K filing, SEC EDGAR — Invitae asset acquisition

$10M upfront + up to $42.5M milestones (cash + litigation credits)

Target

Invitae Reproductive Health

Diagnostics · Diagnostic / genomic

HQ San Francisco, CA · Founded 2012

Non-invasive prenatal screening (NIPS) and carrier screening business — divested reproductive health assets from Invitae's broader genetic testing portfolio

  • Business Wire — Natera press release (Jan 22, 2024)
  • Natera investor relations

Acquirer

Natera (NTRA)

Diagnostics

HQ Austin, TX

Why this buyer

Curated copy from the verified dataset — not an 8-K LLM summary

Acquired Invitae's NIPS and carrier screening customers — consolidates prenatal/reproductive cfDNA testing market under Natera's platform

Evidence ladder

Single-sourceValue disclosed
  1. Secondary (press / IR)

    Business Wire — Natera press release (Jan 22, 2024)

Limitations

  • Single-source or weak corroboration — treat valuation and timing as directional.
  • $10M upfront + up to $42.5M milestones (cash + litigation credits)
  • Pre-deal valuation sourced from: Natera 8-K filing, SEC EDGAR — Invitae asset acquisition. Pre-deal market-cap and funding citations do not corroborate the acquisition.

Valuation peers · Diagnostics

Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.

Insufficient disclosed data

No verified Diagnostics deals meet the peer rule: same deal type, announced within ±3 years, and a disclosed value inside 0.25×–4× of this transaction.

Same-sector adjacency — not valuation peers

These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.

Vs this deal
BioReference Health (clinical, women's health, urology and 4Kscore assets)LabCorpOct 15, 2026
BioReference Health (clinical diagnostics and reproductive & women's health, outside NY/NJ)LabCorpMar 28, 2024

Other verified deals by Natera

Acquirer program history not already listed as a valuation peer or adjacency row.

No further verified deals

Other verified transactions by Natera are already listed above, or none are in the dataset.

Patient empowerment context

Empowerment context — Invitae Reproductive Health

Curated survey mapping

HLTH/Outcomes4Me 2022 surveyed breast cancer patients (n=1,828). Breast cancer care continuum (HLTH 2022). Rows below are analyst-curated mappings to cited survey items — not live patient outcomes for this target.

  • Not recommended genetic testing (NCCN: almost all should)37%cited HLTH 2022

Other curated mappings on these gaps: Biotheranostics, Endomagnetics, Genomic Health, Foundation Medicine

Full cited gap matrix →

Related verified workspaces

Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.

Curated verified dataset v11 · updated 2026-10-19 · 1 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.